Travoprost 3-Month Safety and Efficacy Study

This study consisted of six visits conducted during two sequential phases. The Screening/Eligibility phase included one screening visit and two eligibility visits. A washout period based on previous ocular medication preceded Eligibility Visit 1. Subjects who met all inclusion/exclusion criteria at both eligibility visits were randomized (1:1) at the second eligibility visit. The Treatment phase consisted of three on-therapy visits (Week 2, Week 6, and Month 3).

Inclusion criteria

• Diagnosis of open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) or ocular hypertension.
• Qualifying intraocular pressure at both eligibility visits.
• Understand and sign an informed consent form.
• Other protocol-defined inclusion criteria may apply.

Exclusion criteria

• Women of childbearing potential if pregnant, breast-feeding, or not on adequate birth control.
• Severe central visual field loss in either eye.
• Chronic, recurrent or severe inflammatory eye disease.
• Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to 20/80 Snellen).
• Any abnormality preventing reliable applanation tonometry.
• Hypersensitivity to prostaglandin analogs or to any component of the study medications.
• Therapy with another investigational agent within 30 days prior to the Screening Visit.
• Other protocol-defined exclusion criteria may apply.